Blood Res.  2022 Mar;57(1):69-74. 10.5045/br.2022.2021138.

Myeloproliferative neoplasm with basophilia and abnormality of platelet-derived growth factor receptor a translocation: a case report

• Choi JG
• Cho DY

• KMID: 2527499
• DOI: http://doi.org/10.5045/br.2022.2021138

Figure

• 

  Fig. 1 Bone marrow aspiration demonstrating a lack of particles and peripheral dilution. Immature cells are occasionally noted (×200).

• 

  Fig. 2 Trephine bone marrow biopsy showing approximately 60% cellularity, with increased atypical megakaryocytes and fibrosis (Hematoxylin & Eosin staining, ×200).

Reference

1. Gatter KC, Warnke RA, Jaffe ES, Harris NL, Stein H, Vardiman JW. 1991. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press;Lyon, France: p. 177–8.

2. Andrae J, Gallini R, Betsholtz C. 2008; Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22:1276–312. DOI: 10.1101/gad.1653708. PMID: 18483217. PMCID: PMC2732412.

3. Heinrich MC, Corless CL, Duensing A, et al. 2003; PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 299:708–10. DOI: 10.1126/science.1079666. PMID: 12522257.

4. Cools J, DeAngelo DJ, Gotlib J, et al. 2003; A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 348:1201–14. DOI: 10.1056/NEJMoa025217. PMID: 12660384.

5. Jovanovic JV, Score J, Waghorn K, et al. 2007; Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 109:4635–40. DOI: 10.1182/blood-2006-10-050054. PMID: 17299092.

6. Baxter EJ, Hochhaus A, Bolufer P, et al. 2002; The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA. Hum Mol Genet. 11:1391–7. DOI: 10.1093/hmg/11.12.1391. PMID: 12023981.

7. Curtis CE, Grand FH, Musto P, et al. 2007; Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol. 138:77–81. DOI: 10.1111/j.1365-2141.2007.06628.x. PMID: 17555450.

8. Walz C, Schultheis B, Metzgeroth G, et al. 2005; Transient response to imatinib in an atypical chronic myeloproliferative disease associated with ins(9;4)(q34;q21q31) and a CDK5RAP2-PDGFRA fusion gene. Blood. 106:3281–6. DOI: 10.1182/blood.V106.11.3281.3281.

9. Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. 2005; Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia. 19:792–8. DOI: 10.1038/sj.leu.2403722. PMID: 15772698.

10. Klion AD, Robyn J, Akin C, et al. 2004; Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 103:473–8. DOI: 10.1182/blood-2003-08-2798. PMID: 14504092.

11. Score J, Curtis C, Waghorn K, et al. 2006; Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia. 20:827–32. DOI: 10.1038/sj.leu.2404154. PMID: 16498388.

12. Yigit N, Wu WW, Subramaniyam S, Mathew S, Geyer JT. 2015; BCR-PDGFRA fusion in a T lymphoblastic leukemia/lymphoma. Cancer Genet. 208:404–7. DOI: 10.1016/j.cancergen.2015.04.007. PMID: 26095243.

13. Walz C, Curtis C, Schnittger S, et al. 2006; Transient response to imatinib in a chronic eosinophilic leukemia associated with ins (9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene. Genes Chromosomes Cancer. 45:950–6. DOI: 10.1002/gcc.20359. PMID: 16845659.

14. Golub TR, Barker GF, Lovett M, Gilliland DG. 1994; Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell. 77:307–16. DOI: 10.1016/0092-8674(94)90322-0. PMID: 8168137.

15. Roy A, Groten J, Marigo V, Tomar T, Hilhorst R. 2021; Identification of novel substrates for cGMP dependent protein kinase (PKG) through kinase activity profiling to understand its putative role in inherited retinal degeneration. Int J Mol Sci. 22:1180. DOI: 10.3390/ijms22031180. PMID: 33503999. PMCID: PMC7865299. PMID: 53a204895952414ea72490f1982a779c.

16. Lahortiga I, Akin C, Cools J, et al. 2008; Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion. Haematologica. 93:49–56. DOI: 10.3324/haematol.11836. PMID: 18166785.